Cooperative Agreement UH2CA312695
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $351K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute $276,545 on June 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop genomic risk prediction models for T-cell malignancies. The recipient will identify high-risk genomic features associated with relapse and death in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) stratified by genetic ancestry, then develop and validate risk prediction...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia a $427,064 cooperative agreement on July 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to generate pilot and feasibility data for a planned randomized controlled trial evaluating circulating tumor DNA (ctDNA) screening in individuals with Li-Fraumeni syndrome. The award funds development of pilot and feasibility protocols that will precede a larger national trial assessing the...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute awarded The Children's Hospital Of Philadelphia $744,511 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias and identify therapeutic vulnerabilities in these treatment-resistant leukemic populations. The research investigates molecular characteristics and clinical implications of HSPC-like blasts across major high-risk leukemia...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,908 on August 12, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support multi-modal data integration and functional screening to discover druggable targets in pediatric low-grade glioma. The research integrates imaging, bioinformatics, and cancer biology to identify novel molecular events across the genome, transcriptome, and epigenome in pediatric low-grade gliomas (PLGG), the most...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- The National Cancer Institute awarded the Children's Hospital of Philadelphia a $610,970 cooperative agreement on September 1, 2026, to develop and validate a T cell receptor (TCR)–based biomarker for prediagnostic detection of high-grade serous ovarian carcinomas (HGSOC) using blood specimens collected before clinical diagnosis. The project addresses the clinical challenge that most HGSOC cases are diagnosed at advanced stage (Stage III or IV), when five-year survival is approximately 30...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $738,666 on August 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer CD19 mimotopes for enhancing and repurposing CD19-CAR T cell therapy against hematological malignancies and solid tumors. The recipient will develop a high-affinity CD19 mimotope identified through yeast surface display screening to pair with existing CD19-CAR T products. The linear mimotope, a 10 amino acid peptide, is...
- The National Institutes of Health National Cancer Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $274,676 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support translational research on inherited genetic variation in B-cell acute lymphoblastic leukemia predisposition. The funded research dissects the role of common and rare risk variants in the IKZF1 locus, which encodes a key regulator of B-cell...